Skip to main content

COVID-19 and the effect on cardiovascular diseases, CV clinical trials and CV outcome trials

In this article, Dr. Lazar Mandinov, Sr. Medical Director at Parexel, provides practical guidance for conducting CV clinical trials related to COVID-19.

Download PDF

For clinical researchers involved with COVID-19, understanding its impact on cardiovascular homeostasis and the underlying pathophysiology is essential. In this article, Dr. Lazar Mandinov, Sr. Medical Director at Parexel, outlines the most significant current evidence and uncertainties, and provides practical guidance for conducting clinical trials related to COVID-19.